Delving into the Latest Updates on Mucosis BV with Synapse

Randomized, Doubleblind, Placebo-controlled Trial in Healthy Adults of Safety and Immunogenicity of 2 Intranasal Doses of SynGEM®, an RSV Candidate Vaccine Containing F Glycoprotein Linked to a Bacterium-like-Particle (BLP) Carrier

The study is a double-blind (within dose level), placebo-controlled Phase I study to assess the safety, reactogenicity and tolerability of two intranasal dose levels of SynGEM®: a low dose level (140 μg F-protein/2mg BLPs) and a high dose level ( 350 μg F-protein/5mg BLPs), each administered twice according to a prime-boost schedule 28 days apart at Day 1 and Day 29. The two dose levels will be recruited sequentially.
Immunogenicity end-points will include assessment of humoral and cellular responses at selected time-points.

开始日期2016-10-01

申办/合作机构

Mucosis BV

[+1]

NL-OMON36678 / CompletedN/A

A Phase 1, randomized, double-blind, controlled trial to evaluate the safety and immunogenicity of increasing intranasal doses or of three intramuscular doses of the adjuvant Gram-positive Enhancer Matrix (GEM) administered with a standard dose of trivalent inactivated influenza vaccine (TIV) antigens, compared to a standard dose of TIV antigens administered either intranasally or intramuscularly in healthy adult volunteers; followed by a randomized, double-blind, controlled evaluation of safety - FluGem in healthy adult and elderly volunteers

开始日期2011-03-08

申办/合作机构

Mucosis BV

100 项与 Mucosis BV 相关的临床结果

登录后查看更多信息

0 项与 Mucosis BV 相关的专利（医药）

登录后查看更多信息

100 项与 Mucosis BV 相关的药物交易

登录后查看更多信息

100 项与 Mucosis BV 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床1期

1

临床2期

其他

1

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

福氏志贺菌2a灭活全细胞疫苗(Mucosis BV)	志贺氏菌感染更多	临床2期
Placental malaria vaccine(Mucosis) ( VAR2CSA )	疟疾更多	临床1期
Intranasal respiratory syncytial virus vaccine (Virtuvax)	呼吸道合胞体病毒感染更多	无进展